These results suggest that serum biomarkers of neuroprotection (SIRT1, Nrf2) and inflammation (NLRP3), together with disease duration, are major independent determinants of HRQoL in PD patients, highlighting their potential relevance in monitoring and therapeutic targeting. The gene discussed is SIRT1; the disease is Parkinson disease.